HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Lipid Metabolism

Background:

• Low high-density lipoprotein cholesterol (HDL-C) levels correlate with increased cardiovascular events.
• Therapies aimed at increasing HDL-C have yielded inconsistent clinical benefits.
• Current research emphasizes high-density lipoprotein (HDL) function over mere cholesterol levels.

Purpose of the Study:

• To review the mechanism of cholesterol efflux mediated by HDL.
• To examine the association between cholesterol efflux capacity and cardiovascular disease (CVD) in human studies.
• To discuss ongoing and completed clinical trials of novel therapies targeting HDL cholesterol efflux.

Main Methods:

• Review of existing literature on HDL function and cholesterol efflux.
• Analysis of human studies investigating the link between cholesterol efflux capacity and CVD.
• Summary of clinical trial data for therapies targeting HDL cholesterol efflux.

Main Results:

• HDL is central to reverse cholesterol transport, facilitating cholesterol removal from peripheral cells.
• Cholesterol efflux capacity from macrophages to HDL is associated with atherosclerosis.
• Emerging evidence supports cholesterol efflux capacity as a significant marker for CVD risk.

Conclusions:

• Cholesterol efflux capacity is a critical functional measure of HDL.
• Understanding HDL's role in cholesterol efflux is vital for developing effective CVD therapies.
• Novel therapeutic strategies targeting HDL cholesterol efflux pathways show promise for managing cardiovascular disease.